Isentress was approved in 2007 for patients whose viral counts were rising despite AIDS drug therapy.

FORBES: Innovation

In January, the FDA approved Isentress for use in children older than two years for HIV therapy.

FORBES: Merck Revised To $50 On Strong Pipeline

We expect established drugs like Januvia, Janumet, Isentress and Gardasil to continue to gain sales on broader usage and lend support to growth.

FORBES: Merck Revised To $50 On Strong Pipeline

This morning, Merck announced that a clinical trial had failed to show that giving its HIV drug Isentress once-a-day was as effective as the current twice-a-day dosing schedule.

FORBES: An Innovator's Dilemma For Merck AIDS Drug

As I wrote last year, Isentress was a very difficult drug to develop, requiring more than a decade of tenacious advocacy on the part of a Merck scientist named Daria Hazuda.

FORBES: An Innovator's Dilemma For Merck AIDS Drug

Merck will still make plenty of money on Isentress.

FORBES: An Innovator's Dilemma For Merck AIDS Drug

The excitement about its newer medicines--including the human papillomavirus vaccine Gardasil, the diabetes pill Januvia and the yet to be approved AIDS drug Isentress--along with reduced fears about liability from Vioxx have helped carry the stock.

FORBES: Losing Lipitor